Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962450 | 0.84 | SRC (0.45) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL8962989 | 0.83 | KMT2A (0.48) | LMNAKMT2A | |
| SCHEMBL8962537 | 0.75 | LMNA (0.46) | LMNAKMT2A | |
| SCHEMBL8962533 | 0.74 | KMT2A (0.43) | SOAT1LMNAKMT2A | |
| SCHEMBL9391001 | 0.72 | LMNA (0.44) | LMNAKMT2A | |
| SCHEMBL9059564 | 0.68 | SOAT2 (0.46) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL8618922 | 0.68 | SOAT2 (0.58) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL5188630 | 0.68 | ALDH1A1 (0.54) | LMNAKMT2AFABP3FABP4FABP5 | |
| SCHEMBL7082105 | 0.68 | NLRP3 (0.50) | LMNAKMT2A | |
| SCHEMBL3991483 | 0.68 | SOAT2 (0.51) | SOAT2MYCSOAT1MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | claimed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |